NO20020886L - Nye integrin- <alfa>v<beta>3-inhibitorer - Google Patents

Nye integrin- <alfa>v<beta>3-inhibitorer

Info

Publication number
NO20020886L
NO20020886L NO20020886A NO20020886A NO20020886L NO 20020886 L NO20020886 L NO 20020886L NO 20020886 A NO20020886 A NO 20020886A NO 20020886 A NO20020886 A NO 20020886A NO 20020886 L NO20020886 L NO 20020886L
Authority
NO
Norway
Prior art keywords
alfa
inhibitors
beta
novel integrin
integrin
Prior art date
Application number
NO20020886A
Other languages
English (en)
Other versions
NO20020886D0 (no
Inventor
Alfred Jonczyk
Oliver Schadt
Simon Goodman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20020886L publication Critical patent/NO20020886L/no
Publication of NO20020886D0 publication Critical patent/NO20020886D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Abstract

Oppfinnelsen vedrører nye forbindelser med formel (I) som er biologisk aktive når de er til stede som ligander for integrinet 0^3: X-Y-Z-R'-CH2R2(R4)-CH2-CO-R5 (I), hvor betydningen av X, Y, Z, R1, R2, R4 og R5 er an- gitt i krav l. Oppfinnelsen vedrører også fysiologisk akseptable salter og solvater av forbindelsene.
NO20020886A 1999-08-24 2002-02-22 Nye integrin- <alfa>v<beta>3-inhibitorer NO20020886D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19939981A DE19939981A1 (de) 1999-08-24 1999-08-24 Neue Inhibitoren des Integrins alphavß3
PCT/EP2000/007591 WO2001014338A1 (de) 1999-08-24 2000-08-04 NEUE INHIBITOREN DES INTEGRINS αVβ¿3?

Publications (2)

Publication Number Publication Date
NO20020886L true NO20020886L (no) 2002-02-22
NO20020886D0 NO20020886D0 (no) 2002-02-22

Family

ID=7919343

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020886A NO20020886D0 (no) 1999-08-24 2002-02-22 Nye integrin- <alfa>v<beta>3-inhibitorer

Country Status (17)

Country Link
EP (1) EP1206454A1 (no)
JP (1) JP2003507458A (no)
KR (1) KR20020016651A (no)
CN (1) CN1370147A (no)
AU (1) AU6570500A (no)
BR (1) BR0013504A (no)
CA (1) CA2382850A1 (no)
CZ (1) CZ2002523A3 (no)
DE (1) DE19939981A1 (no)
HK (1) HK1049666A1 (no)
HU (1) HUP0203697A3 (no)
MX (1) MXPA02001861A (no)
NO (1) NO20020886D0 (no)
PL (1) PL352989A1 (no)
SK (1) SK2282002A3 (no)
WO (1) WO2001014338A1 (no)
ZA (1) ZA200202287B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020665A1 (es) 2000-06-15 2002-08-14 Pharmacia Corp ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
ES2436170T3 (es) * 2003-12-03 2013-12-27 The Scripps Research Institute Anticuerpos y péptidos específicos de la integrina alfa II beta3
EP1802618A1 (en) * 2004-10-14 2007-07-04 Pharmacia Corporation Biphenyl integrin antagonists
US10717736B2 (en) * 2016-11-08 2020-07-21 Bristol-Myers Squibb Company Pyrrole amides as alpha V integrin inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325264A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−芳香環置換−３−フェニルプロピオン酸またはアクリル酸誘導体
AU717283B2 (en) * 1996-10-30 2000-03-23 Merck & Co., Inc. Integrin antagonists
EP1061921A4 (en) * 1998-03-10 2005-03-30 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONIST

Also Published As

Publication number Publication date
EP1206454A1 (de) 2002-05-22
KR20020016651A (ko) 2002-03-04
CZ2002523A3 (cs) 2002-05-15
HUP0203697A3 (en) 2004-04-28
HUP0203697A2 (hu) 2003-03-28
WO2001014338A1 (de) 2001-03-01
DE19939981A1 (de) 2001-03-01
SK2282002A3 (en) 2002-06-04
BR0013504A (pt) 2002-05-07
CN1370147A (zh) 2002-09-18
JP2003507458A (ja) 2003-02-25
ZA200202287B (en) 2003-08-27
NO20020886D0 (no) 2002-02-22
AU6570500A (en) 2001-03-19
PL352989A1 (en) 2003-09-22
MXPA02001861A (es) 2004-09-06
HK1049666A1 (zh) 2003-05-23
CA2382850A1 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
NL350075I2 (no)
TR200101744T2 (tr) Fenilglisin türevleri.
IL148903A0 (en) Certain alkylene diamine-substituted heterocycles
MY107740A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
YU69501A (sh) Aktivatori glukokinaze
NO996108L (no) 9-oksinerytromycinderivater
NZ516599A (en) 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
EP1396493A4 (en) HETEROCYCLIC COMPOUNDS
CA2336412A1 (en) Medicament for treatment of diabetes
ES2243579T3 (es) Derivados de pirazolopirideno.
DK1077218T3 (da) Peptidomimetiske forbindelser omfattende RGD-sekvenser, som er nyttige som integrininhibitorer
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
NO981393L (no) Guanidinoproteasehemmere
TR200302288T2 (tr) Terapi için yeni bileşikler ve metotlar.
YU33202A (sh) Jedinjenja o-etar oksima i fungicidi za primenu u zemljoradnji i vrtlarstvu
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
NO20020886L (no) Nye integrin- &lt;alfa&gt;v&lt;beta&gt;3-inhibitorer
NO20020885L (no) &lt;alfa&gt;v&lt;beta&gt;3-integrininhibitorer
MXPA02001406A (es) Heterociclilos-2h-cromenos substituidos.
ES2195500T3 (es) Dereivados del 2-indanometanol y su utilizacion a titulo de ingredientes perfumantes.
AP2001002314A0 (en) Substituted benzolactam compounds.
PL345966A1 (en) N-substituted azabicycloheptane derivatives, production and use thereof
ES2168062A1 (es) Composiciones para control de cucarachas
MXPA03012073A (es) Amidoderivados heterociclicos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application